[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Braile Biomedica Ind. Com. e Repr. Ltda.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100560153",false,"NCT06573437","Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease","Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease - Post Market Clinical Trial Iliac Stent Trial","VESTO-ILIAC","Inclusion Criteria:\n\n1. 18 years of age or older;\n2. TASC-II aortoiliac lesion classification of modified class A, B, C, or D;\n3. Rutherford classification score of 2 to 5;\n4. Access site compatibility with the device delivery system;\n5. Compliance with the device's instructions for use (IFU);\n6. Patient availability for appropriate follow-up times for the duration of the study;\n7. Patient informed about the nature of the study, agreeing to its provisions, and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to heparin, contrast media, or stent components;\n2. Patient with blood dyscrasia;\n3. Pregnant or breastfeeding women;\n4. Patient currently participating in an investigational drug or device study;\n5. Patient undergoing chemotherapy or radiation therapy;\n6. Patient with a stent or graft located in the target limb;\n7. Patient who underwent angioplasty or bypass surgery within 30 days prior to inclusion in this study;\n8. Patient with a life expectancy of less than 12 months;\n9. Inability to undergo dual antiplatelet therapy (DAPT)","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study will validate the efficacy and safety of the VESTO® Vascular Stent for treating patients with iliac peripheral arterial obstructive disease in a post-market clinical trial",[24],"Peripheral Arterial Disease","RECRUITING","2025-03-21",{"date":28,"type":29},"2025-03-26","ACTUAL",{"date":31,"type":29},"2024-06-21",{"date":33,"type":20},"2026-08",{"name":35,"class":36},"Braile Biomedica Ind. Com. e Repr. Ltda.","INDUSTRY",6,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100536877","NCT06270537","Post-market Clinical Trial of the Dominus® Stent-Graft","Multicenter Study Collecting Post-market Clinical Data on the Dominus® Stent-Graft for Treating Thoracic Aortic Diseases","DominusPMCF","Inclusion Criteria:\n\n1. 18 years of age or older;\n2. Patients treated with the Dominus® Stent-Graft Endoprosthesis in accordance with its Instructions for Use;\n3. Patient available for appropriate follow-up times for the study duration;\n4. Informed patient about the nature of the study, agreeing to its provisions, and signing the informed consent.\n\nExclusion Criteria:\n\n1. Patient currently participating in another clinical study of drug or medical device;\n2. Life expectancy less than 12 months.",{"count":19,"type":20},"Real-world clinical trial evidence post-market, evaluating the safety and efficacy of the Dominus® StentGraft Endoprosthesis in treating thoracic aortic diseases, following the Instructions for Use",[48],"Thoracic Aortic Dissection",[50,51,52,53,54],"Aneurysm","Acute Aortic Syndrome","Aortic Dissection","Aortic Diseases","Cardiovascular Diseases","2024-08-21",{"date":57,"type":29},"2024-08-22",{"date":59,"type":29},"2023-10-24",{"date":61,"type":20},"2029-02-28",{"name":35,"class":36},3,""]